Search

Your search keyword '"Petty F"' showing total 349 results
Start Over Author "Petty F" Publication Year Range Last 50 years
349 results on '"Petty F"'

8. Post-traumatic stress disorder and serotonin: new directions for research and treatment

Author

Davis, L L, Suris, A, Lambert, M T, Heimberg, C, and Petty, F

Subjects
Stress Disorders, Post-Traumatic, Serotonin, mental disorders, Humans, behavioral disciplines and activities, Research Article
Abstract

The overlap in clinical phenomenology and morbidity between post-traumatic stress disorder (PTSD) and such conditions as major depression, anxiety disorders and aggression, in which a serotonin dysfunction is implicated, suggests a role for serotonin in the pathophysiology of PTSD. In this paper, we review current knowledge concerning the role of serotonergic mechanisms and interventions in PTSD. Since there is no clearly effective pharmacologic intervention for this disorder, the underlying neurochemical dysfunction needs to be carefully defined so that more effective treatment can be developed. Preclinical and clinical studies of the serotonergic mechanisms in the pathophysiology of PTSD and treatment trials involving serotonergic agents are limited, but indicate considerable promise. Further investigation of a serotonergic dysfunction in PTSD and of its treatment with serotonergic agents is warranted.

Published
1997

27. Plasma GABA predicts response to divalproex in mania

Author

Petty, F., primary, Rush, A.J., additional, Davis, J.M., additional, Calabrese, J.R., additional, Small, J.G., additional, Swann, A.C., additional, Kramer, G.L., additional, Orsulak, P.J., additional, Blake, M., additional, and Bowden, C.L., additional

Published
1995
Full Text
View/download PDF

43. Potential benefits of quetiapine in the treatment of substance dependence disorders.

Author

Sattar SP, Bhatia SC, and Petty F

Abstract

OBJECTIVE: Some antipsychotic medications prescribed for the treatment of psychoses, mood disorders or post-traumatic stress disorder in patients with coexisting substance dependence disorders (SDD) have reduced substance dependence. We studied the potential benefits of quetiapine in the treatment of SDD. METHODS: We conducted a retrospective chart review of data for 9 patients who were admitted to a 28-day residential rehabilitation program designed for individuals with SDD during a 3-month period from January 2003 through March 2003 and treated with quetiapine for nonpsychotic anxiety. These patients also met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria for alcohol, cocaine and/or methamphetamine dependence and substance-induced anxiety disorder. The patients were assessed using the Hamilton-D Rating Scale for Depression (Ham-D), a 10-point Likert scale to measure alcohol or drug cravings, and random Breathalyzer and urine drug screens. RESULTS: Quetiapine was generally well tolerated. Only 1 of the 9 patients stopped taking the medication because of increased anxiety. Other patients reported improvement in sleep and anxiety. The mean decrease in Ham-D score at discharge for the responders was 18.5 (p < 0.005). The biggest decreases on the Ham-D occurred on the subscales of insomnia, agitation, somatic anxiety, psychologic anxiety, hypochondriasis and obsessional symptoms. The mean decrease in the Likert 10-point craving scale was 5.9 for the responders (p < 0.005). These patients' periodic Breathalyzer and urine test results suggested that they remained abstinent from alcohol and other drug use. CONCLUSION: Quetiapine was beneficial in the treatment of SDD in patients with nonpsychotic anxiety. [ABSTRACT FROM AUTHOR]

Published
2004

46. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.

Author

Tohen, Mauricio, Sanger, Todd M., Tohen, M, Sanger, T M, McElroy, S L, Tollefson, G D, Chengappa, K N, Daniel, D G, Petty, F, Centorrino, F, Wang, R, Grundy, S L, Greaney, M G, Jacobs, T G, David, S R, and Toma, V

Subjects
ANTIPSYCHOTIC agents, THERAPEUTICS, BIPOLAR disorder, MENTAL illness treatment
Abstract

Objective: The primary intent of this study was to compare the efficacy and safety of olanzapine and placebo in the treatment of acute mania.Method: The design involved a random-assignment, double-blind, placebo-controlled parallel group study of 3 weeks' duration. After a 2- to 4-day screening period, qualified patients were assigned to either olanzapine (N = 70) or placebo (N = 69). Patients began double-blind therapy with either olanzapine, 10 mg, or placebo given once per day. After the first day of treatment, the daily dose could be adjusted upward or downward, as clinically indicated, by one capsule (olanzapine, 5 mg/day) within the allowed range of one to four capsules. The primary efficacy measure in the protocol was defined as a change from baseline to endpoint in total score on the Young Mania Rating Scale. Clinical response was defined a priori as a decrease of 50% or more from baseline in Young Mania Rating Scale total score.Results: The olanzapine group experienced significantly greater mean improvement in Young Mania Rating Scale total score than the placebo group. On the basis of the clinical response criteria, significantly more olanzapine-treated patients (48.6%) responded than those assigned to placebo (24.2%). Somnolence, dizziness, dry mouth, and weight gain occurred significantly more often with olanzapine. There were no statistically significant differences between the olanzapine-treated and placebo-treated patients with respect to measures of parkinsonism, akathisia, and dyskinesias. No discontinuations of treatment due to adverse events occurred in the olanzapine treatment group.Conclusions: The results from this study suggest that compared with placebo, olanzapine has superior efficacy for the symptoms of acute mania. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results